I nvariant NKT (iNKT)
4 cells are a special T cell population coexpressing NK cell receptors and a TCR consisting of an invariant V␣14J␣18 chain (V␣24J␣15 in humans) and a semivariant TCR ␤-chain that is largely biased toward V␤8.2 (V␤11 in humans), V␤2, and V␤7 (1, 2) . This TCR recognizes glycolipid Ags such as ␣-galactosylceramide (␣-GalCer) and isoglobotrihexosylceramide presented on the MHC class I-like molecule, CD1d (1) (2) (3) . One of most striking characteristics of iNKT cells is their ability to promptly secrete various cytokines, including both IFN-␥ and IL-4, after their TCR ligation, and activated iNKT cells exert perforin-and Fas ligand (FasL) mediated-cytotoxicity (1, 2) . iNKT cells distribute preferentially in the liver, and both iNKT cell-produced cytokines and their cytotoxic activity critically contribute to Con A-induced and ␣-GalCer-induced hepatitis (4 -6) .
NK cell receptors are thought to play roles in controlling iNKT cell responses because NK cell receptors control NK cell and conventional CD8 T cell activation when they interact with their cognate ligands (7, 8) . Qa-1 b , a MHC class I-like molecule, can interact with CD94/NKG2 complexes that are mostly expressed in mice as inhibitory CD94/NKG2A (9 -12) . Thus, the Qa-1 b -CD94/ NKG2A interaction is thought to play an inhibitory role in NK cell responses to self, particularly when interacting with other lymphoid cells (7) (8) (9) (10) (11) (12) (13) . Although CD94/NKG2A, but not other CD94/ NKG2 complexes, are expressed on iNKT cells, their function is still controversial (14, 15) .
In this study we now demonstrate that pretreatment with antagonistic anti-NKG2A/C/E mAb (20d5) significantly augmented Con A-induced hepatic injury even in NK cell-and CD8 T cell-depleted wild-type (WT) mice, gld mice, and IL-4-deficient mice, but not in IFN-␥-, perforin-, or IFN-␥ and perforindeficient mice. Consistently, pretreatment with 20d5 augmented serum IFN-␥ levels and perforin-mediated cytotoxicity of hepatic mononuclear cells (MNC). However, inhibition of NKG2A-mediated signals in the effector phase did not effect cytotoxic activity. NK1
Ϫ iNKT cells preferentially expressed NKG2A and predominantly remained during Con A-induced hepatitis, whereas pretreatment with 20d5 augmented the disappearance of NKG2A-expressing iNKT cells in the liver. These results suggested that CD94/NKG2A negatively regulates iNKT cell responses to Con A and Con A-induced hepatitis, similarly as the CD94/NKG2A inhibitory effect on iNKT cell activation via TCR ligation by specific ligands (14, 15) . Consistently, Con A-induced and ␣-GalCer-induced hepatic injury were severe in CD94/NKG2A-deficient DBA/2J mice compared with CD94/NKG2A-intact DBA/2JJcl mice. Thus, CD94/ NKG2A is a major regulator of iNKT cells when activated via their TCR.
Materials and Methods
Mice C57BL/6 (B6) WT mice and gld mice were obtained from Charles River Japan. B6 IFN-␥-deficient (IFN-␥ Ϫ/Ϫ ) mice, perforin-deficient (perforin Ϫ/Ϫ ) mice, IL-4-deficient (IL-4 Ϫ/Ϫ ) mice, and DBA/2J lacking CD94 (10) were obtained from The Jackson Laboratory. B6 IFN-␥ and perforindeficient (IFN-␥/perforin Ϫ/Ϫ ) mice were bred at the Peter MacCallum Cancer Centre. DBA/2JJcl expressing CD94 were obtained from CLEA Japan. All mice were maintained under specific pathogen-free conditions and used in accordance with the institutional guidelines of Juntendo University (Tokyo, Japan), Niigata University (Niigata Japan), and Peter MacCallum Cancer Centre (East Melbourne, Australia).
Reagents
A synthetic form of ␣-GalCer was provided by Kirin Brewery and was dissolved in pyrogen-free PBS and i.p. injected to mice (6) . PE-conjugated tetrameric CD1d molecules loaded with ␣-GalCer (␣-GalCer/CD1d) were prepared as described (16) . The anti-NKG2A/C/E mAb (20d5) and anti-CD8 mAb (53-6.7) were generated as described previously (14, 17) . Control rat IgG and LPS were purchased from Sigma-Aldrich. A neutralizing anti-mouse FasL mAb (MFL3) was obtained from BD Biosciences. Concanamycin A (CMA), which inhibits perforin-mediated cytotoxicity (18) , and anti-asialo GM1 (ASGM1) Ab were purchased from Wako Pure Chemicals. FIGURE 1. CD94/NKG2A, but not CD94/ NKG2C or E, expression on hepatic iNKT, NK, and conventional CD8 T cells. Cell surface expression of CD94, NKG2A/C/E, and NKG2A was analyzed on electronically gated hepatic iNKT, NK, conventional CD8, and conventional CD4 T cells freshly isolated from B6 mice.
Induction of Con A-induced hepatitis
Con A (Sigma-Aldrich) was dissolved in pyrogen-free PBS and i.v. injected into mice through the tail vein (5) . In some experiments, mice were i.p. administered with 300 g of anti-CD8 mAb and/or 100 g anti-ASGM1 Ab 8 h before treatment with 300 g of 20d5 or isotype-matched control Ig 2 days before Con A injection. Sera from individual mice were obtained 16 h after Con A or 24 h after ␣-GalCer injection. Serum aminotransferase (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) activities were measured by the standard photometric method using a Hitachi type 7350 automatic analyzer (Hitachi).
Flow cytometric analysis
MNC were prepared as described (5 , allophycocyanin-conjugated anti-mouse CD4 mAb (RM4-5), PE-Cy5.5-or allophycocyanin-conjugated anti-mouse TCR ␤ mAb(H57-597), FITC-conjugated anti-mouse CD94 mAb (18d5), biotinconjugated anti-mouse FasL (CD95L, CD178) mAb (MFL3), biotin-conjugated anti-mouse NKG2A B6 mAb (16a11), biotin-conjugated anti-mouse NKG2A/C/E mAb (20d5), biotin-conjugated anti-mouse CD28 mAb (37.51), biotin-conjugated anti-mouse IOCS (CD278) mAb (7E.17G9), FITC-conjugated anti-mouse CD3 mAb (145-2C11), FITC-, PE-, PECy5.5-, allophycocyanin-, or biotin-conjugated isotype-matched control mAbs, PE-conjugated ␣-GalCer/CD1d, and PE-Cy5.5-or allophycocyanin-conjugated streptavidin. All Abs and streptavidins were purchased from eBioscience.
ELISA
IFN-␥ in the sera was determined by using mouse IFN-␥-specific ELISA kits (OptEIA; BD Bioscience) according to the manufacturer's instructions.
Cytotoxicity assay
Cytotoxic activity was tested against FasL-sensitive and NK cell-sensitive YAC-1S cells, FasL-resistant and NK cell-resistant B16 cells, or B6 LPS blast cells by a standard 4-h 51 Cr release assay as previously described (5) . LPS blast cells were prepared as previously described (19) . Effector cells (hepatic and splenic MNC) were prepared from mice 6 h after the i.p. injection of Con A. Some mice were i.p. administered with 300 g of isotype-matched control Ig or anti-NKG2 mAb 2 days before Con A injection. Specific cytotoxicity was calculated as previously described (5) . In some experiments, the cytotoxicity assay was performed in the presence of anti-FasL (MFL-3) mAb (10 g/ml), anti-NKG2A/C/E mAb (20d5) (10 g/ml), and/or CMA (50 nM).
Statistical analysis
Data were analyzed by a two-tailed Student's t test. A value of p Ͻ 0.05 was considered significant.
Results

Aggravation of hepatic injury following blockade of the CD94/NKG2A-mediated signals in Con A-induced hepatitis
It has been reported that activated iNKT cells play critical roles in Con A-induced hepatic injury (4, 5), and we reported that a NKG2A-mediated signal negatively regulated iNKT cell activation by specific ligands (14) . As previously reported using spleen and liver MNC (7) (8) (9) (10) (11) (12) 14) , CD94/NKG2A complexes, but not other CD94/NKG2 complexes, were expressed on iNKT cells, NK cells, and conventional CD8 T cells, whereas conventional CD4 T cells did not express any CD94/NKG2 complex (Fig. 1) . These results clearly suggested that antagonistic anti-NKG2A/C/E mAb (20d5) treatment blocks only the CD94/NKG2A-mediated inhibitory signal and not any potential activating signal. Thus, we examined the role of NKG2A-mediated signals in Con A-induced hepatic injury following treatment with 20d5.
Serum AST and ALT levels were substantially augmented after Con A injection in the 20d5-pretreated mice compared with control Ig-pretreated mice ( Fig. 2A) . These results suggested that NKG2A inhibited Con A-induced hepatic injury possibly by inhibiting lymphocyte activation in response to Con A. NK cells, iNKT cells, and conventional CD8 T cells expressed CD94/NKG2A and were suggested to contribute to Con A-induced hepatic injury (4, 5, 20 -22) ; thus, we next examined the impact of 20d5 treatment on Con A-induced hepatic injury in CD8 T cell-and/or NK cell-depleted mice. The elevation of serum AST and ALT levels by 20d5 pretreatment was highest in control Ig-treated mice, but 20d5 pretreatment also significantly increased serum AST and ALT levels in CD8 T cell-and/or NK cell-depleted mice (Fig. 2B) . Thus, the NKG2A-mediated signal inhibits Con A-induced hepatic injury by suppressing iNKT cell activation, although conventional CD8 T cell and NK cell activation would be also reduced by the NKG2A-mediated signal.
FasL or IL-4 deficiency does not diminish the augmentation of Con A-induced hepatic injury by blockade of the NKG2A-mediated signal
It has been reported that iNKT cell-mediated cytotoxicity (FasLand perforin-dependent killing) and iNKT cell-producing cytokines (IFN-␥ and IL-4) critically contribute to Con A-induced hepatic injury (4, 5) . Thus, we next examined the effect of 20d5 pretreatment on Con A-induced hepatic injury in several genedeficient mice. Pretreatment with 20d5 augmented the elevation of serum ALT and AST levels in FasL-mutant gld mice and IL-4-deficient mice after Con A injection (Fig. 3A) , even when NK cells and CD8 T cells were depleted (Fig. 3B) . However, 20d5 pretreatment did not demonstrate any effect upon ALT and AST levels in Con A-injected perforin-, IFN-␥-, and IFN-␥ and perforin-deficient mice (Fig. 3A) . Thus, the NKG2-mediated signal inhibited Con A-induced hepatic injury by suppressing IFN-␥ production and perforin-mediated killing.
Augmentation of Con A-induced IFN-␥ production but not FasL expression by blockade of the NKG2A-mediated signal in vivo
FasL expression was augmented on hepatic iNKT cells, NK cells, and conventional CD8 T cells after Con A injection, although FasL expression levels on iNKT cells were higher compared with those on NK cells or conventional CD8 T cells (Fig. 4A) . 20d5 pretreatment did not modify FasL expression on iNKT cells, NK cells, or conventional CD8 T cells in both control and Con A-treated mice (Fig. 4A) . Serum IFN-␥ and IL-4 levels were also examined, because we have reported that NKG2A-mediated signals negatively regulate IFN-␥ and IL-4 production from ligand-activated iNKT cells (14) . IL-4 was not detected at any time points after Con A injection even in the 20d5-pretreated mice (data not shown); however, serum IFN-␥ level was increased by 20d5 pretreatment in Con A-injected mice (Fig. 4B) . NK cell and CD8 T cell depletion reduced the serum IFN-␥ level after Con A injection in concert with the contribution of NK cells and CD8 T cells to Con A-induced hepatic injury. Con A-induced serum IFN-␥ elevation was augmented by 20d5 pretreatment in NK cell-and CD8 T celldepleted WT mice (Fig. 4B) , suggesting the inhibitory role of NKG2A in IFN-␥ production by Con A-activated iNKT cells. These results indicated that the NKG2A-mediated signal inhibits IFN-␥ production by iNKT cells, NK cells, and conventional CD8 T cells, but not FasL expression on these cells during Con A-induced hepatic injury.
Augmentation of perforin-mediated cytotoxicity of liver MNC from Con A-injected mice by anti-CD94/NKG2A mAb treatment
We then examined the effect of the NKG2A-mediated signal on the cytotoxic activity of hepatic MNC using NK cell-and FasLsensitive YAC-1S cells and NK cell-and FasL-resistant B16 cells. Cytotoxic activity of hepatic MNC against YAC-1S cells was augmented 6 h after Con A injection in WT mice, and 20d5 pretreatment increased the cytotoxic activity of hepatic MNC in Con A-injected mice, but not control mice (Fig. 5A) . Con Ainduced cytotoxic activity was reduced by NK cell depletion; however augmentation of cytotoxicity by 20d5 pretreatment was observed in NK cell-depleted and NK cell-and CD8 T cell-depleted mice, suggesting that NK cells and iNKT cells mainly exerted cytotoxic activity after Con A injection. B16 cells were still resistant to the cytotoxicity exerted by hepatic MNC 6 h after Con A injection. The cytotoxic activity of hepatic MNC from 20d5-and Con A-treated mice was significantly higher compared with that from Con A-treated mice even when FasL-mediated cytotoxicity was inhibited by anti-FasL mAb (Fig. 5B) . However blockade of perforin-mediated killing by CMA diminished the augmentation of cytotoxic activity by 20d5 pretreatment (Fig. 5B) . Consistently, 20d5 pretreatment significantly augmented cytotoxic activity of hepatic MNC from gld mice, but not that of perforin-deficient mice, following Con A injection (Fig. 5C ). Significant augmentation of cytotoxic activity by 20d5 pretreatment was not found in the experiments using IFN-␥-deficient mice (Fig. 5C ). 20d5 pretreatment did not affect the cytotoxic activity of hepatic MNC in the absence of Con A injection. 20d5 did not have any effect on cytotoxic activity of hepatic MNC against Qa-1 b -expressing B6 LPS blast cells when 20d5 was added during the cytotoxicity assay (Fig. 5D) . Similar results were obtained in the experiments using splenic MNC (data not shown); however, cytotoxic activity was weak compared with that of liver MNC, probably due to a lower number of iNKT and NK cells in spleen. Taken together, these results indicated that the NKG2A-mediated signal inhibited perforin-mediated cytotoxicity due to inhibition of IFN-␥ production responding to Con A, and that NKG2A-mediated signals contribute little to cytotoxic activity during the effector phase.
NKG2A ϩ iNKT cells preferentially remain in liver after Con A injection
As we previously reported (5), the percentage of iNKT cells in the liver MNC quickly decreased after Con A injection (17.7 Ϯ 3.5% in control mice and 3.3 Ϯ 0.6% 6 h after Con A injection). NK1 Ϫ iNKT cells preferentially remained in the liver compared with NK1 ϩ iNKT cells after Con A injection (NK1 ϩ iNKT cells: 10.9 Ϯ 1.8% in control mice and 1.0 Ϯ 0.6% in Con A-injected mice; NK1 Ϫ iNKT cells: 3.8 Ϯ 1.5% in control mice and 2.3 Ϯ 0.6% in Con A-injected mice) (Fig. 6A) . Interestingly, NKG2A was expressed preferentially on NK1 Ϫ iNKT cells, and the NKG2A-expressing population increased in both NK1
Ϫ and NK1 ϩ iNKT cells after Con A injection (Fig. 6A) . Almost all iNKT cells expressed the costimulatory molecule receptors CD28 and IOCS (Fig. 6A ), which were reported to contribute to iNKT cell activation (23, 24) and Con A responses (25) . Moreover, pretreatment with 20d5 appeared to facilitate the disappearance of iNKT cells, particularly enhancing the disappearance of NK1 Ϫ FIGURE 7. Deficiency of CD94/NKG2A in DBA/2 mice augments Can A-induced and ␣-GalCer-induced hepatic injury. A, Impaired CD94 expression in DBA/2J, but not DBA/2JJcl, mice. Hepatic MNC were freshly isolated from the indicated DBA/2 mice substrains, and CD94 expression was examined by flow cytometric analysis. Similar results were obtained using freshly isolated splenic MNC. B, Serum ALT levels in CD94/ NKG2A-deficient DBA/2J and CD94/NKG2A-intact DBA/2 JJcl mice after Con A injection. Mice were i.v. treated with the indicated amounts of Con A, and sera were collected 16 h after injection. Serum samples were obtained from three mice in each group. ‫,ء‬ p Ͻ 0.05 as compared with DBA/2JJcl mice treated with same amount of Con A. C, Serum ALT levels of ␣-GalCer-injected DBA/2 mice. Serum samples were obtained from five mice in each group 24 h after ␣-GalCer (2 g) i.p. injection. Some DBA/ 2JJcl mice were treated with i. iNKT cells (0.6 Ϯ 0.5% in 20d5-pretreated and Con A-injected mice) and keeping the iNKT cell populations similar to those found in normal mice (NK1 ϩ iNKT cells Ͼ NK1 Ϫ iNKT cells) (Fig. 6B) . These results indicated that NKG2A-mediated signaling inhibits activation-induced disappearance of iNKT cells responding to Con A.
Augmentation of Con A-induced and ␣-GalCer-induced and hepatic injury in CD94/NKG2A-deficient mice
We finally examined the effect of genetic deficiency in CD94/ NKG2A-mediated signaling on hepatic injury induced by iNKT cell activation. In concert with a previous report (10) , DBA/2J mice were defective in CD94 expression whereas expression of CD94 was observed in DBA/2JJcl mice (Fig. 7A) . Con A-induced hepatic injury was more obvious in DBA/2J mice compared with DBA/2JJcl mice (Fig. 7B) . Moreover, when these two substrains of DBA/2 mice were treated with i.p. injection of ␣-GalCer, CD94-deficient DBA/2J mice suffered more severe hepatic damage compared with CD94-intact DBA/2JJcl mice, and 40% of these died of hepatic injury just 3 days following ␣-GalCer injection (Fig. 7C , left panel, D, and E). 20d5 pretreatment augmented hepatic injury induced by ␣-GalCer in DBA/2JJcl mice (Fig. 7C , right panel, and F) similarly as that induced by Con A in B6 mice. Taken together, these results clearly demonstrated that a CD94/NKG2A-mediated signal negatively regulates hepatic injury induced by Con A and the iNKT cell-specific ligand ␣-GalCer.
Discussion
iNKT cells preferentially distribute to liver and have been demonstrated to play critical roles in antitumor immune responses and protection from infectious disease (1, 2) . It has been reported that activation of hepatic iNKT cells triggers hepatic injury following iNKT cell specific ligand, ␣-GalCer, or Con A injection (4 -6), and NK cells and conventional CD8 T cells may also play roles (20, 22) . In this study we reported that blockade of a NKG2A-mediated inhibitory signal by mAb (20d5) resulted in the augmentation of Con A-induced serum IFN-␥ elevation and hepatic injury even when NK cells and CD8 T cells were depleted. Serum AST and ALT levels were augmented by 20d5 pretreatment in WT, gld, and IL-4 deficient mice, but not in IFN-␥-or/and perforin-deficient mice. Consistently, 20d5 pretreatment augmented perforin-mediated killing, but not FasL expression or FasL/Fas-mediated killing, and this augmentation of perforin-mediated killing was not observed in Con A-treated, IFN-␥-deficient mice. Moreover, cytotoxic activity was not augmented when 20d5 was added to the cytotoxicity assay. Thus, CD94/NKG2A contributes to Con A-induced hepatic MNC activation, particularly iNKT cell activation, to produce IFN-␥ that enhanced perforin-mediated cytotoxic activity. In concert, impaired CD94/NKG2A in the DBA/2 mice substrain resulted in more severe ␣-GalCer-induced and Con A-induced hepatic injury.
Previous studies have shown that iNKT cells disappear quickly after activation by anti-CD3 mAb, iNKT cell-specific ligands, Con A, and IL-12 treatment due to activation-induced cell death (5, 26, 27) and/or down-regulation of cell surface functional molecules (TCR, costimulatory molecule receptors, and NK cell receptors) (14, 15, 28 -30) . Regardless, the disappearance of iNKT cells is thought to be an early sign of iNKT cell activation. We have thus demonstrated the following: 1) Con A injection decreased iNKT cells in vivo; 2) NKG2A-expressing NK1
Ϫ iNKT cells preferentially remained following Con A injection; 3) the NKG2A-expressing population increased among both NK1
Ϫ and NK1 ϩ iNKT cells after Con A injection; and 4) 20d5 pretreatment appeared to facilitate the disappearance of iNKT cells, particularly NKG2A-expressing NK1 Ϫ iNKT cells, after Con A injection. These results suggested that NKG2A inhibited the iNKT cell response to Con A. In concert, we have reported that CD94/NKG2A negatively controls iNKT cell activation by the iNKT cell-specific ligands ␣-GalCer and OCH (14) . Inhibitory Ly49 receptors, which recognize MHC class I directly, have also been reported to suppress ␣-GalCer-induced iNKT cell activation (31) . CD94/NKG2A is more frequently expressed on iNKT cells than Ly49 (14, 15) ; thus, CD94/NKG2A may play a more dominant role in regulating iNKT cell activation than Ly49 and may maintain self-tolerance of iNKT cells and help to avoid any pathogenic effect of iNKT cell activation (32, 33) . Further, by using TAP-deficient mice in vitro, CD94/NKG2A was reported to play no role in splenic iNKT cell activation by ␣-GalCer (15) . Thus, the magnitude of the inhibitory effect of CD94/ NKG2A-mediated signaling on iNKT cells might be variable among iNKT cell subsets, activation status, various tissues, and their microenvironments, and/or the experimental conditions (34) .
Con A-induced hepatitis is a popular model of autoimmune hepatitis, and the hepatic injury is transient (35, 36) . Fas/FasL-mediated killing, perforin-mediated killing, IFN-␥, IL-4, and TNF-␣ were reported to play a role in Con A-induced hepatic injury (4, 5, 20, 21, 35, (37) (38) (39) . We have reported that Qa-1 b , a ligand for CD94/NKG2A, is inducible by IFN-␥ (14) . It has been shown that CD94/NKG2A expressed on NK cells and conventional CD8
ϩ T cells suppressed their activation (7) (8) (9) 12) . Thus, IFN-␥-mediated Qa-1 b up-regulation may be a negative feedback mechanism for overactivation of NK cells, iNKT cells, and conventional CD8 T cells, and resulting in transient hepatic injury. It will be interesting to explore the role of CD94/NKG2A in other iNKT cell-mediated biological responses, anticancer activity, or infectious diseases using Qa-1 b -deficient (40) or CD94-deficient (10) mice. CD94/NKG2A is reported to inhibit activation of NK cells and conventional CD8 T cells (7) (8) (9) 12) , and both cells are reported to play a substantial role in Con A-induced hepatic injury (20, 22) . Activated NK cells might be mainly responsible for cytotoxic activity rather than iNKT cells, because sustained IFN-␥ production and cytotoxicity following iNKT cell activation were mediated by NK cells secondarily activated by IFN-␥ derived from iNKT cells and IL-12 derived from dendritic cells (27, 41, 42) . Hence, elevation of serum AST, ALT, and IFN-␥ levels and cytotoxic activity by 20d5 pretreatment in Con A-injected mice were reduced by CD8 T cell and/or NK cell depletion. It is also possible that conventional CD4 T cells play a role in IFN-␥ production and FasLmediated cytotoxicity induced by Con A injection (43) . However, conventional CD4 T cells do not express CD94/NKG2A and FasL does not play a major role in augmented cytotoxicity following 20d5 treatment. Thus, augmentation of hepatic injury, serum IFN-␥ level, and cytotoxic activity by 20d5 pretreatment in NK cell-and CD8 T cell-depleted mice clearly indicated augmentation of iNKT cell activation by blockade of the CD94/NKG2A-mediated inhibitory signal. CD94/NKG2A possibly plays inhibitory roles in lymphocyte activation (including iNKT cells, NK cells, and conventional CD8 T cells) when iNKT cells are activated by Con A and their specific ligands in vivo. However, aggravation of ␣-GalCer-induced hepatic injury by CD94 deficiency was higher when compared with that of Con A-induced hepatic injury in DBA/2 mice, and this result suggests a dominant inhibitory role of CD94/NKG2A on activated iNKT cells rather than NK cells and conventional CD8 T cells.
In this study we showed that hepatic NK1 Ϫ iNKT cells preferentially express NKG2A and that blockade of NKG2A-mediated inhibitory signals accelerated activation of NK1
Ϫ iNKT cells rather than NK1 ϩ iNKT cells and augmented Con A-and ␣-GalCer-induced hepatic injury. It was recently reported that NK1 Ϫ iNKT cells, but not NK1 ϩ iNKT cells, produce IL-17 that plays a critical role in the onset and progression of some cell-mediated autoimmunity and immune-mediated inflammatory diseases (44 -46) . Con A-induced hepatic injury is thought to be a cell-mediated immunoinflammatory disease similar to human autoimmune hepatitis (36) . Thus, selective enhancement of IL-17-producing NK1 Ϫ iNKT cell activation might also play a critical role in the augmentation of Con A-and ␣-GalCer-induced hepatic injury by 20d5 treatment as well as augmentation of IFN-␥ production and perforin-mediated cytotoxicity by iNKT cells, NK cells, and conventional CD8 T cells. Further studies are now ongoing to reveal the role of IL-17 in iNKT cell-mediated hepatic injury, although examination of activated iNKT cells is technically difficult due to their prompt disappearance.
CD94/NKG2A blockade might be also applicable to improve the antitumor effect of ␣-GalCer in humans. In addition to an antitumor effect, ␣-GalCer has been shown to protect mice against infections and autoimmune diseases (1, 2, 47, 48) . Therefore, the blockade of CD94/NKG2A may be also applied to improve the therapeutic effect of ␣-GalCer in these diseases. However, it has been also shown that ␣-GalCer occasionally induces tissue pathologies (6, 32, 33) and exacerbated autoimmune diseases depending on the model and/or administration protocol (49) . In these cases, signal induction through inhibitory NK cell receptors including CD94/NKG2A might prevent tissue damage. Therefore, further studies are needed to determine the optimal protocol to modulate NK cell receptor-mediated signals in iNKT cell-targeting therapy for the safe treatment of tumor, infections, and autoimmune diseases.
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